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ABSTRACT 
Background: Asymptomatic meningioma is a common incidental finding with no consensus 
on the optimal management strategy. We aimed to develop a prognostic model to guide 
personalized monitoring of incidental meningioma patients. 
Methods: A prognostic model of disease progression, defined as: symptom development, 
meningioma-specific mortality, meningioma growth or loss of window of curability, was 
developed in a retrospective cohort (2007–2015). Secondary endpoints included non-
meningioma-specific mortality and intervention.  
Results: 441 patients (459 meningiomas) were included. Over a median of 55 months (IQR 
37-80), 44 patients had meningioma progression and 57 died (non-meningioma-specific). 
Forty-four had intervention (at presentation [n=6], progression [n=20], non-progression 
[n=18]). Model parameters were based on statistical and clinical considerations and included: 
increasing meningioma volume (HR 2.17 [95% CI 1.53–3.09]), meningioma hyperintensity 
(HR 10.6 [95% CI 5.39–21.0]), peritumoral signal change (HR 1.58 [95% CI 0.65–3.85]) and 
proximity to critical neurovascular structures (HR 1.38 [95% CI 0.74–2.56]). Patients were 
stratified based on these imaging parameters into low-, medium- and high-risk groups and 5-
year disease progression rates were 3%, 28% and 75% respectively. After 5-years of follow-
up, the risk of disease progression plateaued in all groups. Patients with an age-adjusted 
Charlson comorbidity index≥6 (e.g. an 80-year old with chronic kidney disease) were 15-times 
more likely to die of other causes than to receive intervention at 5-years following diagnosis, 
regardless of risk-group.  
Conclusions: The model shows that there is little benefit to rigorous monitoring in low-risk 
and older patients with comorbidities. Risk-stratified follow-up has the potential to reduce 
patient anxiety and associated healthcare costs. 
Keywords: Asymptomatic; Incidental; Meningioma; Prognosis; Risk score
N-O-D-19-00312R1 
3 
 
KEY POINTS 
• Most incidental meningiomas do not progress during follow-up 
• Risk of incidental meningioma progression plateaus after 5-years of follow-up 
• Baseline imaging and clinical factors can be used to guide personalized monitoring  
 
IMPORTANCE OF THE STUDY 
Incidental meningioma is common with no consensus on the optimal management strategy. 
International guidelines recommend monitoring with MRI for managing these tumors, however 
details regarding the optimal duration and intervals for follow-up are lacking.  This often 
prompts clinicians to commence long-term follow-up, which is of uncertain patient benefit and 
has economic implications. Using data from 441 patients with incidental meningiomas, we 
developed a prognostic model which can be used to predict an individualized disease 
progression risk and tailor monitoring. Our study showed that most incidental meningiomas 
remain stable during follow-up and that growth plateaus after 5 years. Tumor hyperintensity, 
increasing meningioma volume, proximity to critical neurovascular structures and peritumoral 
signal change all increase the risk of disease progression within the first 5-years following 
diagnosis. To aid clinical decision-making, these imaging factors, alongside patient age, 
comorbidity and performance status were used to build the IMPACT calculator, freely 
available to clinicians (www.impact-meningioma.com).  
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INTRODUCTION 
Wider access and increased use of brain imaging has led to a marked rise in the number of 
incidental findings in clinical and research settings, including meningiomas.1 Incidental 
meningiomas cause patient anxiety and uncertainty around the need for future treatment and 
often prompt clinicians to commence long-term follow-up.  International consensus guidelines 
suggest active monitoring with magnetic resonance imaging (MRI) as first line for managing 
these tumors,2 however, data to support the optimal duration and intervals for follow-up are 
lacking.3 Several studies have identified prognostic imaging factors that are associated with the 
risk of meningioma growth and development of clinical symptoms,4,5 however the timing of 
such progression is poorly defined. Moreover, clinical factors such as patient comorbidity and 
performance status remain unexplored in relation to prognosis but are equally important for 
clinical decision-making.  The patient with an incidental meningioma wants to know whether 
their tumor will grow and become symptomatic such that it will require (safe) treatment within 
their (healthy) lifetime. The aim of this study was to combine routinely available imaging and 
clinical factors to develop a prognostic model for the risk of incidental meningioma progression 
during active monitoring. 
MATERIALS AND METHODS  
Study design 
We performed a retrospective cohort analysis of adults (age≥16 years) with a newly identified 
incidental asymptomatic meningioma between January 2007 and December 2015, with follow-
up through to March 2018. Patients with radiation-induced and neurofibromatosis type II 
associated meningiomas and with incomplete medical records were excluded. The study setting 
was the Walton Centre NHS Foundation Trust, the only specialist stand-alone neuroscience 
hospital in the UK. It serves a catchment area of 3.5 million people and has service partnerships 
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with 18 other hospitals. The Institutional Review Boards at the authors’ institutions approved 
this study.  
Study endpoints 
Primary composite endpoint  
Symptom development, meningioma-specific mortality, development or increase of 
peritumoral signal intensity (vasogenic edema), venous sinus invasion or meningioma volume 
exceeding 10 cm3. The first two criteria denoted clinical progression while the latter three are 
related to loss of window of curability. Venous sinus invasion and peritumoral edema can 
prevent complete surgical resection.6,7 Peritumoral edema and a meningioma volume>10 cm3 
are relative contraindications to stereotactic radiosurgery (SRS).8,9 
Secondary endpoints 
The occurrence of an intervention and mortality unrelated to the meningioma.  
Baseline predictive variables 
Patient age, sex, the World Health Organization (WHO) performance status (PS)10 and the age-
adjusted Charlson comorbidity index (ACCI)11,12 were derived from the medical records. 
Imaging variables assessed were: (i) number of meningiomas, (ii) calcification on non-contrast 
computed tomography (CT) (diffuse/partial/absent), (iii) tumor signal intensity compared to 
the contralateral grey matter on T2-weighted (T2) or fluid attenuated inversion recovery 
(FLAIR) MRI (hypo/iso/hyper), (iv) peritumoral signal intensity in relation to tumor volume 
using the signal change present on T2/FLAIR MRI (0-5%/6-33%/34-66%/67-100%13) and (v) 
meningioma volume using the ABC/2 formula on contrast-enhanced T1-weighted MRI/CT: 
(A) maximum meningioma diameter on axial plane, (B) diameter perpendicular to (A) and (C) 
maximum height on coronal/sagittal plane. Meningioma location was classed into non-skull 
base and skull base and further subcategorized according to the Internal Consortium on 
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Meningioma classification system.3 Meningiomas in proximity to major dural venous sinuses 
(superior sagittal/transverse/sigmoid/cavernous/torcula) were categorized as separate (≤10 
mm), in direct contact with its wall or invading. Contact with critical neurovascular structures 
(e.g. optic apparatus) was noted. Meningiomas that fulfilled one of the two previous categories 
were said to be in proximity to critical neurovascular structures. Inter- and intra-observer 
reliability of imaging parameters were assessed on a random sample of 24 patients (sample size 
determined using the Bland equation14) by two observers (A.I.I. and M.M.) using weighted 
Cohen’s Kappa or the intraclass correlation coefficient as appropriate. 
Statistical analysis  
Two series of analyses were undertaken. Firstly, to determine an appropriate definition of 
meningioma growth, and secondly to inform the prognostic model. Where appropriate, 
differences across groups were explored with the χ2 test for categorical variables and a one-
way analysis of variance or Kruskal-Wallis test for continuous variables. Normally distributed 
variables were expressed as mean (standard deviation [SD]) whereas skewed variables were 
expressed as median (interquartile range [IQR]). Correlation between baseline variables was 
evaluated using the Pearson correlation coefficient. Differences were considered statistically 
significant at P<0.05. Analyses were performed using R v3.5.0 and SPSS v24.0. 
1. Meningioma growth definition  
There is no agreed standard definition of meningioma growth.15 For standardization across 
untreated incidental meningiomas, we used existing measures – extent of growth and annual 
growth rate.3 To determine which is most appropriate, we conducted a series of analyses to 
examine the temporal relationship between disease progression and meningioma volume.   
The association between baseline variables and the initial composite disease progression 
endpoint was assessed using Kaplan-Meier (KM) analysis. Statistical significance was 
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examined using the Log-rank test. Patients who did not experience disease progression and 
remained under observation were censored at the last recorded follow-up. Patients discharged 
from outpatient care, deceased during follow-up or lost to follow-up were censored at the last 
date of follow-up, where there was no evidence of disease progression.  
To determine how longitudinally changing meningioma volume is associated with the hazard 
for disease progression, a joint longitudinal and time-to-event model was fitted. The 
longitudinal sub-model was comprised of a linear mixed-effect regression model for 
meningioma volume (natural logarithm) and included both the random intercept and slope. The 
survival sub-model was comprised of a time-varying covariate semi-parametric Cox 
proportional hazards model, which included patient level meningioma volume predicted from 
the longitudinal sub-model. The final joint model included baseline variables with P≤0.10. 
Standard errors and P values of the estimated model parameters were obtained using 200 
bootstrap samples.  
Extent of growth or annual growth rate definitions, based on the statistical effect of time, were 
examined in relation to our initial criteria of disease progression. A classification and 
regression tree (CART) analysis was used to assess the degree of success by which these 
definitions can set our cohort apart stratified by disease progression. 
2. Prognostic model  
KM analysis, using initial composite endpoint and adopted meningioma growth definition, was 
performed as described above. A Cox regression model was subsequently developed. 
Backward and forward stepwise selection procedures were utilized to determine the model of 
best fit with covariate inclusion at P≤0.05 and exclusion at P≥0.10. Skewed continuous 
variables were transformed into their natural logarithms before being inputted into the model. 
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Certain covariates were included despite being statistically non-significant due to their clinical 
importance.  
A prognostic index was developed based on the results of the Cox model. This was calculated 
for each patient as the sum of the covariate values included in the final model, weighted by the 
normal logarithmic transformation of the hazard ratios.  
Risk group stratification was carried out by visual assessment of a prognostic index histogram. 
The prognostic index for each patient was plotted along the y-axis whilst the frequencies of 
observed disease progression and non-progression were plotted on the x-axis. Wherever a 
noticeable increase in the proportion of disease progression occurred in relation to the 
frequency of non-progression, a cut-off line was drawn. This was carried out twice to best 
separate the study cohort into three distinct risk groups: low-, medium- and high-risk. The 
probabilities of progression-free survival by 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years were then 
calculated for each of these groups with KM analysis used to assess differences across them.  
Model assumptions were examined using Schoenfeld residuals and bootstrapping was 
performed to assess its internal validity (with 200 samples). Calibration was assessed using 
plots of observed versus predicted disease progression at 5- and 10-years following diagnosis 
in sextiles of predicted risk. Discrimination was assessed using Harrell's concordance-statistic 
and Chambless and Diao’s time-dependent area under the receiver operating characteristic 
curve.16,17  
The effect of patient age, comorbidity and performance status on the risk of disease progression 
and intervention were assessed in a competing risk analysis. Patients with normal (PS 0) or 
limited activity who were ambulatory and able to carry out light work (PS 1) at the time of 
diagnosis were grouped and compared against ambulatory patients capable of all self-care but 
unable to carry out any work activities (PS 2), those in a chair/bed for ≥50% of the day but not 
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bedridden (PS 3) and bedridden patients (PS 4). Patients were also stratified by ACCI into: 0-
2 (young patients with few or no comorbidities), 3-5 (older patients with few comorbidities or 
younger patients with several comorbidities) and ≥6 (older patients with comorbidities).18 
Two competing risk analyses were performed. One assessing the cumulative incidence rate 
(CIR) of intervention following diagnosis stratified by ACCI and PS groups. The other 
evaluated the CIR of disease progression. The competing event for the former was non-
meningioma-specific mortality which was observed either during follow-up or after being 
discharged from outpatient care. Patients who remained under follow-up were censored at the 
last outpatient clinic appointment. Patients discharged alive from outpatient care were censored 
at the last time they were seen by a healthcare physician. For the disease progression analysis, 
competing events were: discharge from outpatient care, loss to follow-up, death during follow-
up or an intervention before disease progression occurred with the first three grouped together. 
Censoring was done for patients who remained under follow-up at the last clinic appointment. 
The Fine and Gray test was carried out to test equality across groups.  
Additional analyses 
Due to the lack of a standardized surveillance protocol at our centre, the growth rate for each 
meningioma was determined using a linear mixed model which does not require regularly 
spaced time points, assuming a different intercept and slope for each meningioma. Absolute 
growth rate (AGR) was defined as the increase in volume per year in cm3 whereas relative 
growth rate (RGR) was defined as the percentage increase in volume per year. 
RESULTS 
Study population and baseline characteristics 
A total of 441 patients were included (Supplementary Figure S1); 18.5% of all meningioma 
patients identified and 9.10% of incidental neurological findings. The number of patients 
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identified per year increased in a linear fashion (Supplementary Figure S2). Meningiomas were 
solitary in 426 patients and multiple in 15, resulting in an overall meningioma population of 
459. Baseline characteristics are summarized in Supplementary Table S1.    
Treatment arms and outcomes  
At initial presentation, six patients underwent surgical resection, 50 were discharged and the 
remaining 385 patients (403 meningiomas) commenced active monitoring (median 36.0 
months [IQR 18.0-57.0]). Differences in baseline characteristics across the treatment groups 
are shown in Supplementary Table S1. The total number of scans performed following 
diagnosis in the active monitoring group was 1303 (3.4/patient); 1166 had MRI whilst the 
remainder had CT. Most patients (n=360) were consistently monitored using the same imaging 
modality: MRI in 317 patients and CT in 43. The remaining 25 patients were followed-up 
alternately with CT and MRI. Overall outcomes by the end of the study period were: discharged 
(n=219), under continued observation (n=205), lost to follow-up (n=12) and deceased during 
follow-up (unrelated to the meningiomas) (n=5). Records for patients discharged or lost to 
follow-up were examined (median 34.0 months [IQR 20.0-56.0]) and 52 patients died after a 
median of 18.5 months (IQR 11.3-37.0) of termination of follow-up. The median overall 
follow-up duration was 55.0 months (IQR 37.0-80.0). 
Meningioma growth endpoint 
The joint model showed that time is strongly associated with the initial composite endpoint 
(P<0.001) (Supplementary Tables S2 and S3) and since meningioma growth is likely to precede 
these endpoints, and certain factors such as surgical intervention might have prevented their 
occurrence, it is reasonable that survival analyses incorporate tumor volume change over time 
(annual rate) as an additional endpoint. The CART analysis for the growth endpoint AGR≥2 
cm3/year OR AGR≥1 cm3/year+RGR≥30%/year19 demonstrated a superior misclassification 
rate and improvement score to other time-dependent growth definitions (see Supplementary 
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Figures S3 and S4). Therefore, disease progression in our study was defined using the initial 
composite endpoint in addition to the aforementioned growth endpoint.   
Disease progression and intervention  
During follow-up, 44 (10.9%) patients had meningioma progression. Endpoints included: 
meningioma growth (n=29), new symptom development (n=12), increase in peritumoral signal 
change (n=10), meningioma volume exceeding 10 cm3 (9/369 with an initial volume<10 cm3) 
and venous sinus invasion (5/137 adjacent to but not invading a sinus). Symptoms were seizure 
(n=6), motor deficit (n=3), visual deficit (n=2) and ataxia (n=1). Twenty-eight experienced one 
disease progression endpoint whereas 16 had multiple (12 patients, n=2; three patients, n=3; 
one patient, n=4). Median time to disease progression was 33.0 months (IQR 15.0-46.5). The 
5- and 10-year progression-free survival rates were 83.0% (95% CI 77.1-88.9) and 70.0% (95% 
CI 56.3-83.7) respectively. The mean longitudinal profiles for meningioma volume against 
time relative to disease progression are shown in Figure 1; if two equally sized meningiomas 
were detected at the same point in time, the meningioma with growth potential will have 
reached its disease progression endpoint by the 75th month following diagnosis.   
Rates of intervention and its prerequisite recommendation were significantly lower in the non-
progression group (Table 1; P<0.001). In the disease progression group, an intervention was 
recommended in 37 patients but only carried out in 20. Median time to intervention in both 
cohorts was 24.0 months (IQR 11.8-42.0).  
When treatment was offered for imaging reasons alone (disease progression group, n=11; non-
progression group, n=4), patients tended to decline since they were clinically stable. Disease 
progression in six patients additionally involved new symptom development which patients 
either elected to control with antiepileptics (seizure, n=5) or were happy to live with due to 
their minimal impact on quality of life (visual field deficit, n=1). Of the 12 patients who 
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progressed and had further imaging surveillance available, 11 continued to show evidence of 
meningioma growth (median follow-up period after initial disease progression 21.0 months 
[IQR 13.5-24.0]). Three patients with epilepsy had controlled seizures at their last follow-up, 
despite continued meningioma growth in two patients (mean follow-up period after initial 
disease progression 16.0 months [SD=2.8]). 
Prognostic model 
KM analyses (Supplementary Table S4) revealed male sex (P=0.005), increasing tumor volume 
(P<0.001), absence of calcification (P<0.001), peritumoral signal change (P<0.001) and 
T2/FLAIR hyperintense meningioma (P<0.001) to be significantly associated with disease 
progression. Following backward stepwise regression analysis (Table 2; model 1), two 
prognostic factors were identified: T2/FLAIR hyperintense meningioma, and meningioma 
volume (natural logarithm). Absence of calcification was not included in the model as 
hypointensity on T2/FLAIR acts a surrogate for calcification on CT (bivariate correlation, 
P<0.001). Forward stepwise regression was subsequently performed to examine the prognostic 
importance of variables with a significance level P>0.10, together with interaction terms of 
prognostic factors identified in the first model and variables excluded from the first analysis. 
No additional factors were identified. Two imaging parameters were however deemed 
clinically important and were included in the model, namely proximity to critical neurovascular 
structures and peritumoral signal change (model 2).  
Based on the results of model 2, a prognostic index (Figure 2A) was generated for each patient 
and plotted against the observed frequencies of progression and non-progression in a histogram 
(Figure 2B). Risk group stratification was performed by visual assessment and appropriate 
partitioning by cut-off points allowing for the creation of three distinct risk groups: low-risk 
(<1), medium-risk (<3) and high-risk (≥3). KM analysis (Figure 2C) demonstrated a significant 
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difference (P<0.001) in the probabilities of progression-free survival (Figure 2D) following 
diagnosis across risk groups.   
CIR plots of disease progression and intervention are shown in Figure 3 (and Supplementary 
Tables 5 and 6). Stratified by ACCI, the rates of intervention were statistically different across 
the three groups (P<0.001), although the rates of disease progression were not (P=0.090). 
Approximately 80% of patients with an ACCI≥6 were discharged, deceased or lost to follow-
up at 5-years following diagnosis, having not had disease progression. Patients with an ACCI≥6 
were also 15-times more likely to die within 5-years of follow-up than to receive an 
intervention. Patients with an ACCI 0-2 were three times more likely to have experienced 
disease progression at 5 years compared to patients with an ACCI≥6. The rates of intervention 
and mortality did not differ in patients with an ACCI 3-5. Differences in incidence rates of 
disease progression and intervention among the PS groups were statistically significant 
(P<0.001). No patient with a PS 2-4 had disease progression or intervention. The rates of 
intervention and mortality did not differ in patients with a PS 0-1. 
Model and data validity  
The diagnostic parameters of the model demonstrated adequate internal validity (see 
Supplementary Table S7 and Figures S5 and S6). Assessment of inter- and intra-observer 
variability across imaging factors showed a good level of agreement (Supplementary Table 
S8).  
DISCUSSION  
In this study of incidental asymptomatic meningiomas, tumor hyperintensity, increasing 
meningioma volume, proximity to critical neurovascular structures and peritumoral signal 
change increased the risk of disease progression within the first 10 years following diagnosis. 
Based on these factors, patients can be stratified into three risk groups with differing monitoring 
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strategies assigned to each. Patients with an ACCI≥6 and PS 2-4 are unlikely to require an 
intervention for their incidental meningiomas during their estimated lifetimes and thus do not 
require continued imaging surveillance. These clinical and imaging factors have been grouped 
to create a prognostic model that can aid clinicians and patients to reach a shared-care decision 
about management. 
Imaging factors on MRI and CT  
Previous studies have focused on imaging factors that predict meningioma growth and these 
were also identified in our study. Meningioma hyperintensity is strongly associated with 
progression5,20 along with peritumoral signal change (indicative of vasogenic edema due to 
breach of the arachnoid plane).21,22  The presence of calcification on non-contrast CT was 
highly correlated with tumor signal intensity on T2/FLAIR and thus was not included as a 
separate variable in our model.  T2, FLAIR and susceptibility weighted sequencing have all 
been shown to reliably delineate meningioma related calcification,23 which is a feature of 
meningiomas that tend to display a much more indolent clinical course.24,25 The two imaging 
factors - tumor signal intensity and edema - are not always the main features considered for 
decision making. Rather, meningioma location and initial volume tend to be key factors for 
clinicians to recommend early intervention.19  Whilst we do not fully agree with this approach 
as both surgery and radiotherapy have side effects, we do however acknowledge the need to 
monitor larger meningiomas in certain anatomical locations more closely and this was 
accounted for in the prognostic model. Loss of ‘window of curability’ is also important to 
consider. Tumor volume >10 cm3 precludes use of SRS and sinus invasion can limit the 
effectiveness of surgery.7,8 Offering treatment before these endpoints are reached makes the 
assumption that the risk of treatment is lower than the risk of continued surveillance and 
delayed treatment, which might not be the recommendation of the clinician,  but could still be 
chosen by the patient. Meningiomas in eloquent/skull base locations are also at a higher risk of 
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causing major morbidity compared to convexity meningiomas. Thus, although not statistically 
significant in multivariate analysis, proximity to critical neurovascular structures was added to 
the prognostic model. It should however be noted that non-skull base meningiomas constitute 
the majority of those discovered incidentally.3 Despite the importance of identifying prognostic 
factors for growth, there are no studies that examine the duration of follow-up required for 
incidental meningiomas. Our results indicate that most patients with incidental meningiomas 
at risk of disease progression requiring consideration of treatment will experience progression-
related events within the first five years of follow-up.  
Age, comorbidity and performance status  
Patient factors are equally as important as MRI characteristics for clinical decision-making. 
We used the age-adjusted Charlson comorbidity index which when combined with 
performance status can be used to further stratify the risk of future intervention. Patients were 
split by ACCI into two groups: <6 and ≥6. An ACCI≥6 denotes older patients with 
comorbidities (e.g. an 80-year old with hypertension and type II diabetes mellitus). Although 
a minority of patients with an ACCI≥6 experienced disease progression, we did not observe 
any interventions during prolonged follow-up. The lack of treatment intervention is due to: (i) 
the high rate of mortality prior to progression; patients were 15-times more likely to die than 
to receive an intervention at 5 years following diagnosis and (ii) the threshold for intervention 
in these patients was much higher. Older patients with comorbidities should not be subject to 
surgery or radiation solely due to imaging changes as the risk of morbidity and mortality far 
outweighs the treatment benefit.26,27 For these reasons we propose that patients with an 
ACCI≥6 can be discharged from outpatient care with reassurance that their meningiomas are 
unlikely to cause them problems during their estimated life-times. A similar finding was 
observed in patients with a performance status of 2-4 and a similar management strategy could 
be employed.28  
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Active monitoring strategies 
Comprehensive guidelines for the management of incidental meningioma are lacking,2 and 
there is wide variation in routine clinical practice.29 The development of practice parameters 
should ideally consider individual patient and imaging factors that can aid clinical decision-
making, similar to those used for unruptured intracranial aneurysms.30 Our proposed 
monitoring strategy is demonstrated in Figure 4. Based on the prognostic imaging and clinical 
factors, incidental meningioma patients can be divided into five groups. Low- and medium-
risk patients with an ACCI≥6 or PS 2-4 can be discharged with no subsequent clinical or 
imaging monitoring but should be counselled about the symptoms that might warrant further 
examination. Patients in the remaining four categories require follow-up but with varying 
frequencies. High-risk patients with an ACCI≥6 or PS 2-4 can be followed clinically with 
imaging offered on clinical progression only. Low-, medium- and high-risk patients with an 
ACCI<6 and a PS 0-1 can be followed clinically and radiologically but with different time 
points corresponding with the rates of disease progression (see Figure 2D). At each 
appointment, growth rates in concordance with disease progression (AGR≥2 cm3/year OR 
AGR≥1 cm3/year+RGR≥30%/year), peritumoral signal intensity, the relationship with 
neighbouring neurovascular structures, and the potential to miss the ‘window of curability’ 
should be examined. Based on any observed changes, a recommendation for treatment or a 
decision to continue follow-up can be made and tailored to each patient.   
Beyond 10 years of follow-up 
Prognosis beyond 10 years of follow-up for incidental meningioma remains unclear. One study 
reported growth, defined as >2 mm progression in any unidimensional diameter, beyond 10 
years.31 However, the results of the joint model used to define disease progression in our study 
indicated that the rate of tumor growth is of greater clinical importance. Reassessment of ACCI 
and PS at extended follow-up (beyond 10 years) is also important since older patients with new 
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comorbidities, but who remain radiologically and clinically stable, can be safely discharged 
from outpatient care. Patients with a longer life expectancy on the other hand appear to pose 
an ongoing management dilemma. Based on our observations that imaging changes indicating 
an intervention are more likely to occur within the first 5 years of follow-up, longer term 
imaging surveillance might not be necessary and instead infrequent clinical monitoring could 
be adopted.  
Study limitations 
Some limitations of the study should be noted.  First, this was a single-centre retrospective 
cohort study with varying non-standardized follow-up schedules. Nevertheless, appropriate 
statistical methods were used to account for this. Second, the use of intervention as an endpoint 
was limited by patient and clinician biases and might have influenced the results of the 
competing risk analyses. Our tumor board considers the clinical and radiological status of the 
meningioma, performance status and comorbidities before discussion of the recommended and 
alternate management strategies with the patient and making a shared-care decision. Due to the 
retrospective study design, we were unable to ascertain the exact reasons for continued 
monitoring in cases of progression, however surmise that this was due to patient preference 
(considering personal and social circumstances, employment, loss of driving license for at least 
6 months in the UK, risk of post-treatment epilepsy, new neurological deficit and death). Third, 
the selection process of a growth endpoint was limited by use of our data set only and by 
inevitable competing events such as surgery and radiation, which might have masked the 
occurrence of the initial composite endpoint. A larger number of events are required to verify 
our findings and to potentially stratify growth definition by anatomical location. Fourth, we did 
not have any data on patient quality of life, though it should be noted that most patients 
remained under follow-up with the majority reporting no change in clinical symptoms, which 
supports the notion that most patients with an incidental meningioma lead normal lives – a 
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supposition supported by the limited published quality of life studies.32,33  Fifth, patient anxiety 
and satisfaction with follow-up frequency was not assessed.  ‘Scanxiety’ is a well-recognized 
phenomenon for cancer patients and it is reasonable to assume a similar experience for patients 
with non-malignant brain tumors.34 The impact on patient well-being, of more or less frequent 
monitoring needs further research. Lastly, socioeconomic status was not assessed. Comorbidity 
burden and functional status reflect social class and are related to increased risk of 
mortality.28,35 Moreover, access to clinic appointments and treatment is free and available to 
all patients within the UK’s National Health Service care system and so it was unlikely that 
social class had an impact on our observation of study endpoints, given the low rate of loss to 
follow-up (2.7%). However, patients with minimal non-specific symptoms from lower 
socioeconomic backgrounds are less likely to present to healthcare, which might have reduced 
the population size and confounded the data.  
Future work 
To keep with reported standards of prognostic models in oncology36, further validation with 
external retrospective datasets is required. Based on a disease progression risk of 11%, data for 
a minimum of 1000 patients (100 events37) will be needed. Nevertheless, our dataset comprised 
of a large number of patients that are representative of the general meningioma population with 
associated comorbidity and included a variety of meningioma volumes and locations. 
Moreover, the parameters associated with internal validation (including discrimination and 
calibration) demonstrated adequate accuracy. A free online resource has been developed based 
on our results - the IMPACT (Incidental Meningioma: Prognostic Analysis Using Patient 
Comorbidity and MRI-Tests) calculator (www.impact-meningioma.com). 
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CONCLUSIONS  
IMPACT offers a personalized active monitoring approach for patients with incidental 
meningioma and has the potential to reduce the healthcare costs and patient uncertainty about 
the need for future treatment. By incorporating clinical and imaging factors into the prognostic 
model, the need for follow-up and the frequency of imaging can be determined based on the 
risk of meningioma growth stratified by patient age, comorbidity and performance status. 
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FIGURE LEGENDS  
Figure 1. Profile plot for meningioma volume against reverse time stratified by disease 
progression status. Bold curves are LOESS (locally fitted estimated scatterplot smoothing) 
curves. Whilst incidental meningiomas that did not progress remained static in size during 
follow-up, meningiomas that did, exponentially grew prior to reaching a disease progression 
endpoint. The time-course over which disease progression occurred is denoted by the dotted 
intersection line. It shows that if two equally sized meningioma as were picked up at the same 
point in time, the meningioma with growth potential will reach its disease progression endpoint 
by the 75th month (~6th year) following diagnosis. 
Figure 2. (A) A 1.50 cm3 hyperintense convexity meningioma distant from critical 
neurovascular structures unaccompanied by peritumoral signal change. Using the prognostic 
index (LN1.50×Ln2.17) + (1×LN10.6) + (0×LN1.58) + (0×LN1·38) = 2.8, this meningioma 
could be classified as Medium risk. (B) Histogram of the disease progression and non-
progression cases plotted against the prognostic index demonstrating the two cut-off lines. (C) 
KM plot stratified by risk group. (D) Table with the non-progressions probabilities at different 
time points following diagnosis stratified by risk group. LN=normal logarithm. 
Figure 3. (A-B) Estimated cumulative incidence curves (solid lines) for disease progression 
and its competing events with 95% CIs (shading) stratified by (A) ACCI and (B) PS. (C-D) 
Estimated cumulative incidence curves (solid lines) for intervention and mortality with 95% 
CIs (shading) stratified by (C) ACCI and (C) PS. DP: disease progression; DDFU: deceased 
during follow-up; HD: hospital discharge; LTFU: lost to follow-up.    
Figure 4. Proposed active monitoring strategies of incidental meningiomas. Time intervals in 
shaded boxes are our proposed time-points for follow-up. 
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Table 1. Differences in growth dynamics and intervention outcomes between the 
progression and non-progression groups.   
Characteristic Disease progression 
(N=44) 
Non-progression (N=359) P 
Median AGR/year in cm3 
(IQR) 
1.36 (0.72-2.58) 0.05 (0.01-0.17) <0.001a 
Median RGR/year in % 
(IQR) 
26.7 (14.5-38.8) 4.13 (0.81-8.39) <0.001a 
Intervention 
recommended, N (%) 
37 (84.1) 16 (4.46) <0.001b 
Intervention, N (%) 20 (45.5) 18 (5.01) <0.001b 
Intervention as per patient 
request, N (%) 
0 (0.00) 6 (1.67)c 0.789b 
AGR=absolute growth rate; RGR=relative growth rate; SD=standard deviation 
aKruskal-Wallis test 
bχ2 test 
cRequested surgery after a median follow-up period of 4.5 months (IQR 3.0-15.0). 
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Table 2. Hazard ratios (95% CI) of statistically and clinically important factors in 
multivariate analysis  
 Model 1a  Model 2  
Factor  HR (95% CI) P HR (95% CI) P 
Meningioma volume 
(natural logarithm) 
2.43 (1.82-3.24) <0.001 2.17 (1.53-3.09) <0.001 
Meningioma 
hyperintensity  
11.2 (5.72-21.9) <0.001 10.6 (5.29-21.0) <0.001 
Peritumoral signal 
change  
- - 1.58 (0.65-3.85) 0.313 
Proximity to critical 
neurovascular structures 
- - 1.38 (0.74-2.56) 0.314 
CI=confidence interval; HR=hazard ratio 
aResults of the backward stepwise regression, investigating the set of variables with a Log-rank p≤0·10 
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Supplementary Table S1. Patient demographics and clinical and radiological characteristics  
Characteristic   
All 
patients 
(N=441) 
Active 
monitoring 
(N=385) 
Discharged 
(N=50) 
Surgery 
(N=6) 
P 
Indication for imaging, N 
(%) 
 
     
Headache  114 (25.9)     
Cerebrovascular accident  61 (13.8)     
Audiovestibular 
symptoms 
 
57 (12.9)     
Head trauma  35 (7.9)     
Cognitive deficits  27 (6.1)     
Visual problems  22 (5.0)     
Loss of consciousness  18 (4.1)     
Others  107 (24.3)     
Age (years), mean (SD)  
 63.3 
(12.6) 
62.6 (12.0) 68.5 (15.9) 
63.8 
(10.5) 
0.008b 
Sex, N (%)       
Female  348 (78.9) 301 (86.5) 41 (11.8) 6 (1.7) 0.365c 
Male  93 (21.1) 84 (90.3) 9 (9.7) 0  
ACCI, N (%)       
0-2  103 (23.4) 94 (91.3) 9 (8.7) 0 0.002c 
3-5  212 (48.1) 193 (91.0) 15 (7.1) 4 (1.9)  
≥6  126 (28.6) 98 (77.8) 26 (20.6) 2 (1.6)  
WHO PS, N (%)       
0-1  387 (87.8) 346 (89.4) 35 (9.0) 6 (1.6) 0.001c 
2-4  54 (12.2) 39 (72.7) 15 (27.8) 0  
Meningioma counta, N 
(%) 
 
     
Single  426 (96.6) 370 (86.9) 50 (11.7) 6 (1.4) 0.323c 
Multiple 2 13 (2.9) 13 (100) 0 0  
 3 1 (0.2) 1 (100) 0 0  
 4 1 (0.2) 1 (100) 0 0  
Meningioma volume 
(cm3)a, median (IQR) 
 
1.6 (0.6-
4.0) 
1.7 (0.7-4.2) 
0.7 (0.3-
1.4) 
10.6 (4.2-
21.6) 
<0.001d 
Meningioma locationa, N 
(%) 
      
Non-skull base Convexity  183 (39.9) 150 (82.0) 30 (16.4) 3 (1.6) 0.478c 
 Parafalcine 77 (16.8) 69 (89.6) 8 (10.4) 0  
 Parasagittal 36 (8.2) 35 (97.2) 0 1 (2.8)  
 Tentorial 21 (4.6) 20 (95.2) 0 1 (4.8)  
 Intraventricular 5 (1.1) 5 (100) 0 0  
Skull base Sphenoid wing 45 (9.8) 39 (86.7) 5 (11.1) 1 (2.2)  
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 Posterior fossa-
lateral & 
posterior 
42 (9.2) 38 (90.5) 4 (9.52) 0  
 Anterior 
midline 
34 (7.4) 32 (94.1) 2 (5.9) 0  
 Posterior fossa-
midline  
16 (3.5) 15 (93.8) 1 (6.3) 0  
Venous sinus 
involvementa, e, N (%) 
      
No  291 (63.6) 246 (84.5) 42 (14.4) 3 (1.0) 0.043c 
Yes 
Separate (within 
10 mm) 
49 (10.5) 45 (91.8) 3 (6.1) 1 (2.0)  
 In direct contact 98 (21.4) 92 (93.9) 5 (5.1) 1 (1.0)  
 Invading 21 (4.6) 20 (95.2) 0 1 (4.8)  
Neurovascular structures 
contacta, f, N (%) 
 
     
Yes  35 (7.6) 33 (94.3) 2 (5.7) 0 0.447c 
No  424 (92.4) 370 (87.3) 48 (11.3) 6 (1.4)  
Calcification statusa, N 
(%) 
 
     
Absent  81 (17.6) 75 (92.6) 4 (4.9) 2 (2.5) <0.001c 
Partial  74 (16.1) 68 (91.9) 4 (5.4) 2 (2.7)  
Diffuse  109 (23.7) 80 (73.4) 28 (25.7) 1 (0.9)  
Tumor signal intensitya, N 
(%) 
 
     
Hyper  75 (16.3) 72 (96.0) 2 (2.7) 1 (1.3) 0.052c 
Iso  210 (45.8) 197 (93.8) 9 (4.3) 4 (1.9)  
Hypo  119 (25.9) 104 (87.4) 14 (11.8) 1 (0.8)  
Peritumoral signal 
intensitya, N (%) 
 
     
0-5%  373 (81.3) 345 (92.5) 25 (6.7) 3 (0.9) <0.001c 
6-33%  16 (3.5) 16 (100) 0 0  
34-66%  13 (2.8) 11 (84.6) 0 2 (15.4)  
67-100%  2 (0.4) 1 (50.0) 0 1 (50.0)  
ACCI=Age-adjusted Charlson comorbidity index; IQR=interquartile range; PS=performance status; SD=standard 
deviation; WHO=World Health Organization  
aFor 459 meningiomas  
bOne-way analysis of variance  
cχ2 test 
dKruskal-Wallis test 
eVenous sinus involvement was noted for 168 meningiomas: superior sagittal sinus (n=95), cavernous sinus (n=35), 
sigmoid sinus (n=21), transverse sinus (n=15) and the torcula (n=2).  
fThirty-five meningiomas were in contact with ≥1 critical neurovascular structures and these included: optic apparatus 
(n=17), internal carotid artery (n=11), basilar artery (n=7), trigeminal nerve (n=4), middle cerebral artery (n=2) and the 
vertebral artery (n=2). 
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Supplementary Table S2. Primary Kaplan-Meier analyses used to inform the joint 
longitudinal and survival model of incidental meningioma progression 
Factor  HR (95% CI) P 
Meningioma hyperintensity  13.5 (6.18-29.4) <0.001 
Calcification  32.2 (4.26-243) <0.001 
Peritumoral signal intensity  6.27 (2.87-13.7) <0.001 
Meningioma size <1 cm Reference  
 1-2 cm 2.07 (0.27-16.0) 0.484 
 2-3 cm 6.03 (0.78-46.9) 0.086 
 ≥3 cm 16.7 (2.05-136) 0.009 
 Overall   <0.001 
Proximity to neurovascular structures  1.99 (0.98-4.03) 0.050 
Location Non-skull base Reference  
 Skull base 1.78 (0.89-3.57) 0.103 
Number of meningiomas Single Reference  
 Multiple 1.05 (0.32-3.45) 0.940 
Sex Female  Reference  
 Male  2.39 (1.12-5.08) 0.020 
Age <50 Reference   
 50-59 1.32 (0.48-3.64) 0.593 
 60-69 0.91 (0.33-2.45) 0.845 
 70-79 0.71 (0.20-2.53) 0.598 
 ≥80 1.31 (0.15-11.1) 0.807 
 Overall   0.840 
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Supplementary Table S3. Joint model parameter estimates 
Component Parameter Parameter estimate 
(95% CI) 
P 
Longitudinal Intercept 0.14 (-0.04-0.31) 0.103 
 Time 0.006 (0.005-0.007) <0.001 
 Tumor signal intensity 0.60 (0.23-0.94) <0.001 
 Peritumoral signal intensity 1.45 (1.01-1.94) <0.001 
 Proximity to neurovascular structures 0.37 (0.11-0.60) 0.003 
 Location -0.09 (-0.36-0.14) 0.483 
 Sex 0.12 (-0.20-0.39) 0.469 
Survival Tumor signal intensity 2.66 (1.81-3.92) <0.001 
 Peritumoral signal intensity 1.24 (0.16-2.62) 0.041 
 Proximity to neurovascular structures 0.65 (-0.25-1.73) 0.161 
 Location 0.66 (-0.29-1.63) 0.150 
 Sex 0.23 (-0.88-1.32) 0.678 
Association Meningioma volume and survival 0.93 (0.57-1.52) <0.001 
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Supplementary Table S4. Kaplan-Meier analyses used to inform the prognostic model 
Factor  HR (95% CI) P 
Meningioma hyperintensity  13.3 (6.87-25.7) <0.001 
Calcification  22.7 (5.34-96.7) <0.001 
Peritumoral signal intensity  6.67 (3.39-13.1) <0.001 
Meningioma size <1 cm Reference  
 1-2 cm 3.01 (0.40-22.6) 0.284 
 2-3 cm 8.53 (1.13-64.7) 0.038 
 ≥3 cm 26.7 (3.41-209) 0.002 
 Overall   <0.001 
Proximity to neurovascular structures  1.63 (0.90-2.95) 0.100 
Location Non-skull base Reference  
 Skull base 1.27 (0.69-2.32) 0.452 
Number of meningiomas  Single Reference  
 Multiple 0.97 (0.35-2.74) 0.962 
Sex Female Reference  
 Male 2.41 (1.29-4.56) 0.005 
Age <50 Reference  
 50-59 1.19 (0.49-2.93) 0.699 
 60-69 0.87 (0.36-2.07) 0.747 
 70-79 1.08 (0.40-2.91) 0.873 
 ≥80 1.94 (0.40-9.32) 0.410 
 Overall   0.820 
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Supplementary Table S5. Cumulative incidence rates of disease progression and its 
competing events at diagnosis and at 5 years. 
Event Factor 
 
At diagnosis  5 years  P 
Disease progression ACCI 0-2 0.00 15.7% 0.090 
  
3-5 0.00 12.4%  
  
>5 0.00 6.43%  
 
PS 0-1 0.00 12.8% P<0.001 
  
2-4 0.00 0.00  
HD/LTFU/DDFU ACCI 0-2 8.49% 26.0% <0.001 
  
3-5 6.81% 52.8%  
  
>5 19.5% 82.0%  
 
PS 0-1 8.66% 51.0% P<0.001 
  
2-4 27.3% 82.5%  
Intervention ACCI 0-2 0.00 13.5% 0.009 
  
3-5 1.81% 5.76%  
  
>5 1.50% 1.50%  
 
PS 0-1 1.48% 7.27% P<0.001 
  
2-4 0.00 0.00  
ACCI=age-adjusted Charlson comorbidity index; DDFU=deceased during follow-up; HD=hospital discharge; 
LTFU=lost to follow-up; PS=performance status.   
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Supplementary Table S6. Cumulative incidence rates of intervention and its 
competing event at diagnosis and at 5 years. 
Event Factor 
 
At diagnosis  5 years  P 
Intervention ACCI 0-2 0.00 26.2% P<0.001 
  
3-5 1.81% 9.56%  
  
>5 1.50% 2.26%  
 
PS 0-1 1.49% 13.9% <0.001 
  
2-4 0.00 0.00  
Mortality ACCI 0-2 0.00 1.02% P<0.001 
  
3-5 0.00 9.74%  
  
>5 0.00 33.6%  
 
PS 0-1 0.00 10.4% 0.011 
  
2-4 0.00 45.3%  
ACCI=age-adjusted Charlson comorbidity index; PS=performance status 
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Supplementary Table S7. Prognostic model parameters   
Schoenfeld residualsa Chambless and Diao’s 
time depended AUCb 
Concordance statisticsb 
Factor Test value Time-point Value Type Value 
Overall 
model 
0.964 5-years 0.87 Harrel’s 
statistic 
0.89 (95% CI 0.85-
0.93) 
Meningioma 
volume 
0.662 10-years 0.84   
Tumor signal 
intensity 
0.824     
Peritumoral 
signal 
intensity 
0.691     
Proximity to 
neurovascular 
structures 
0.637     
aTests were all not statistically significant. The proportional hazards assumption in the prognostic model were 
therefore not violated.   
bTime-dependent AUC values and concordance statistics demonstrated excellent discriminative ability 
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Supplementary Table S8. Weighted Kappa values assessing the inter- and 
intraobserver variability among categorical variables 
  Weighted Kappa (95% CI) 
Parameter Inter-observer variability Intra-observer variability 
Calcification 0.82 (0.65-0.99) 0.85 (0.69-1.01) 
Tumour signal intensity  0.80 (0.62-0.98) 0.83 (0.66-1.01) 
Peritumoural signal 
intensity 
0.79 (0.55-1.02) 1.00 (1.00-1.00) 
Venous sinus invasion  0.75 (0.53-0.97) 0.86 (0.67-1.05) 
 Intraclass correlation coefficient (95% CI) 
 Inter-observer variabilitya Intra-observer variabilityb 
Meningioma volume 0.985 (95% CI 0.966-0.999) 0.997 (95% CI 0.993-0.999) 
aSet to two-way mixed 
bSet to one-way random  
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Supplementary Figure S1. Study population selection process 
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Supplementary Figure S2. Number of incidental meningioma 
diagnoses per calendar year  
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Supplementary Figure 3. CART analysis demonstrating the split in 
the active monitoring cohort stratified by disease progression and 
non-progression using AGR≥2 cm3/year OR AGR≥1cm3/year + 
RGR≥30%/year to define growth 
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Supplementary Figure 4. CART analysis demonstrating the split in 
the active monitoring cohort stratified by disease progression and 
non-progression using AGR>1 cm3/year to define growth 
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Supplementary Figure S5. Schoenfeld residual plot for each of the covariates. The solid line is 
a smoothing spline fit to the plot, with the dashed lines representing a ± 2-standard-error band 
around the fit. None of the plots demonstrated a regular pattern with time, and tests were all not 
statistically significant. The proportional hazards assumption in model the prognostic model 
were therefore not violated. 
N-O-D-19-00312R1 
 
 
Supplementary Figure S6. (A-B) Calibration plots at 5 and 10 years respectively. Predicted 
values are plotted on the x-axis and observed values are plotted on the y-axis. The blue bars 
represent the 95% CIs. Calibration plots demonstrated overall a good level of agreement 
between the observed and predicted values however some optimism was observed towards the 
lower probabilities at 5 years and pessimism was noted towards the larger probabilities at 10 
years 
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